Effects of antidiabetic drugs on epicardial fat

doi:10.4239/wjd.v9.i9.141

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6651)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

568

HTML

3551

Figures (1-1)

227

Tables (1-1)

266

Sum=4612

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

788

Download

1251

Sum=2039

Sep 15, 2018 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Sep 15, 2018; 9(9): 141-148
Published online Sep 15, 2018. doi: 10.4239/wjd.v9.i9.141

Effects of antidiabetic drugs on epicardial fat

Eleni Xourgia, Athanasia Papazafiropoulou, Andreas Melidonis

Eleni Xourgia, Athanasia Papazafiropoulou, Andreas Melidonis, 1^st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, Athens 18536, Greece

Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

Conflict-of-interest statement: No potential conflicts of interest. No financial support.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Athanasia Papazafiropoulou, MD, MSc, PhD, Attending Doctor, Research Scientist, 1^st Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, 1 Zanni and Afentouli Street, Athens 18536, Greece. pathan@ath.forthnet.gr

Telephone: +30-697-996483

Received: April 20, 2018
Peer-review started: April 21, 2018
First decision: June 8, 2018
Revised: June 19, 2018
Accepted: June 28, 2018
Article in press: June 28, 2018
Published online: September 15, 2018
Processing time: 147 Days and 8.6 Hours

Core Tip

Core tip: In this review, we aim to create a concise overview of the pathophysiology concerning the epicardial fat deposits on a type 2 diabetic individual, while, delving into the intricacies of each antidiabetic drug and exploring the manner by which it interacts with visceral fat accumulation in the sub-pericardial space.